FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Center | Date | Time | Location |
---|---|---|---|
CDER | February 26, 2004 February 27, 2004 |
8 a.m. - 5 p.m. 8 a.m. - 5 p.m. |
Hilton |
Agenda:
The committee will discuss the following topics: (1) The effectiveness of the
isotretinoin risk management program for the prevention of fetal exposure to
ACCUTANE and its generic equivalents, and (2) consider whether changes to this
isotretinoin risk management program would be appropriate
Background material and meeting information will become available no later than the day before the meeting (Simply select the appropriate year and committee link).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by February 16, 2004. Oral presentations from the public will
be scheduled between approximately 11 a.m. and 12 noon on February 26, 2004,
and between approximately 8:30 a.m. and 9:30 a.m. on February 27, 2004. Time
allotted for each presentation may be limited. Those desiring to make formal
oral presentations should notify the contact person before February 16, 2004,
and submit a brief statement of the general nature of the evidence or arguments
they wish to present, the names and addresses of proposed participants, and
an indication of the approximate time requested to make their presentation.
Persons attending FDA's advisory committee meetings are advised that the agency
is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Shalini Jain at least 7 days in advance of the meeting.
Contact Person:
Shalini Jain, Center for Drug Evaluation and Research (HFD–21),
Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630
Fishers Lane, rm. 1093) Rockville, MD 20857, 301–827–7001, e-mail:
jains@cder.fda.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington,
DC area), code 3014512535 or 3014512534. Please call the Information Line for
up-to-date information on this meeting.
[ Full FR Notice ]